EGFR酪氨酸激酶抑制剂在难治性软脑膜转移NSCLC中的活性
这项多中心回顾性研究纳入92例EGFR突变NSCLC伴软脑膜转移患者,中位年龄60岁,女性68%,从不吸烟者74%。TKI再挑战患者的中位LM总生存为7.6个月(95%CI 5.7-10.9),未进一步治疗者为4.2个月(95%CI 1.6-6.7);60%再挑战患者获得临床获益。
要点
- EGFR突变NSCLC伴LM患者中位总生存为6.1个月(95%CI 4.2-7.6)。
- TKI再挑战者中位LM总生存7.6个月,未进一步治疗者4.2个月。
- 60%再挑战患者获临床获益,23%在6个月时无治疗失败。
核心结论
- TKI再挑战策略(包括剂量强化)可能改善初始TKI治疗失败后EGFR突变NSCLC伴LM患者的临床结局。
研究设计与样本
- 多中心回顾性研究,纳入92例EGFR突变NSCLC伴LM患者。
- TKI失败定义为TKI治疗期间诊断LM或已知LM在TKI治疗期间进展。
主要发现
- 92例患者中位年龄60岁,女性68%,从不吸烟者74%,L858R占45%,19外显子缺失占28%,其他突变占14%。
- 从晚期NSCLC初诊至LM诊断的中位时间为18.5个月,LM诊断前中位接受2线(范围0-9)全身治疗。
- 从LM诊断起中位总生存为6.1个月(95%CI 4.2-7.6)。
- 87例TKI失败患者中,再挑战TKI者(n=50)中位LM总生存为7.6个月(95%CI 5.7-10.9),未进一步治疗者为4.2个月(95%CI 1.6-6.7)。
- 再挑战TKI患者中60%获临床获益(临床缓解或疾病稳定>2个月),23%在6个月时无治疗失败。
关键数值与推荐
- 阿法替尼或吉非替尼后使用厄洛替尼的20例患者中11例(55%)获临床获益。
- 基于增加剂量强度的策略(n=17)在59%患者中产生临床获益。
- 第一、二代TKI后接受奥希替尼的全部4例患者均获临床获益。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Leptomeningeal metastases (LMs) are associated with dismal prognosis in NSCLC. Optimal management remains unknown in patients with EGFR-mutated NSCLC after initial tyrosine kinase inhibitor (TKI) failure. METHODS: We conducted a multicenter retrospective study including patients with EGFR-mutated NSCLC and LM. TKI failure was defined as diagnosis of LM on TKI, or progression of known LM on TKI. RESULTS: Ninety-two patients were included, median age of 60 years, predominantly female (68%), never-smokers (74%). EGFR mutations included L858R (45%), exon 19 deletions (28%), or other mutations (14%). Median time to LM diagnosis was 18.5 months after initial diagnosis of advanced NSCLC. LM was diagnosed after a median of 2 (range: 0-9) systemic therapies. Median overall survival from LM diagnosis was 6.1 months (95% confidence interval [CI]: 4.2-7.6 months). Among 87 patients with TKI failure, patients rechallenged with TKI (n = 50) had a median LM overall survival of 7.6 months (95% CI: 5.7-10.9) compared to 4.2 months (95% CI: 1.6-6.7) in patients without further therapy. Overall, 60% of patients rechallenged with TKI experienced clinical benefit (clinical response or stable disease >2 months), and 23% were treatment failure-free at 6 months. Clinical benefit was reported in 11 of 20 (55%) patients treated with erlotinib after afatinib or gefitinib. Strategies based on increasing dose intensity (n = 17) yielded clinical benefit in 59% of patients. All four patients who received osimertinib after first- and second-generation TKI experienced clinical benefit. CONCLUSIONS: TKI rechallenge strategies, including dosing intensification, may improve clinical outcomes of patients with LM from EGFR-mutated NSCLC after initial TKI failure.
引用
- Flippot R, Biondani P, Auclin E, et al. Activity of EGFR Tyrosine Kinase Inhibitors in NSCLC With Refractory Leptomeningeal Metastases. J Thorac Oncol. 2019. PMID: 31108248. doi:10.1016/j.jtho.2019.05.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。